[en] Objective: To explore the clinical significance of measurement on the changes of serum Hcy hs-CRP and TGF-β₁ levels after treatment in patients with ACI. Methods: Serum Hcy(with immunochemistry), serum hs-CRP(with immunoturbidimetry), serum TGF-β₁ (with RIA) levels were determined in 32 patients with ACI and 35 normal healthy controls. Results: Before treatment, serum Hcy, hs-CRP and TGF-β₁ levels in the patients were significantly higher than those in controls (P < 0.01). After treatment for l month, serum Hcy, hs-CRP and TGF-β₁ levels were no significant difference(P > 0.05). Serum Hcy level showed positively correlated with hs-CRP, TGF-β₁ levels(r = 0.6146, 0.5784, P < 0.01). Conclusion: Detection the changes of serum Hcy, hs-CRP and TGF-β₁ levels after treatment in patient with ACI might be helpful to monitor efficacy of therapy and prognosis. Therefore, possess important clinical value. (authors)